Trial · NCT01137695
Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus
NCT01137695, Phase 3, Unknown, Cheryl Rosenfeld, DO
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus. Trials, record NCT01137695. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01137695
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus
- NCT number
- NCT01137695
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Cheryl Rosenfeld, DO
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Pramlintide, Pramlintide, Pramlintide, Pramlintide
- First posted
- 2010-06-04
- Last updated
- 2011-10-14
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Glucose control | 6 months | A1c Fasting plasma glucose Post-prandial glucose Glycomark |
| Secondary | Weight loss | 6 months | Weight, BMI, Waist circumference. |
| Secondary | amylin level | initial | does initial blood amylin level correlate with need for higher dose pramlintide? |
| Secondary | glucagon level | 6 months | Does change in glucagon level correlate with glycemic response. |
| Secondary | adverse effects | 6 months | Whether or not the rate of common adverse effects exceeds the maximum FDA approved pramlintide (Symlin®) dose of 120 mcg TID (as compared to the clinical practice study) - GI: nausea 30% and Hypoglycemia: medically assisted 0.7% or patient ascertained 0.7%. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01137695
GET https://conductscience.org/api/trials/v1/NCT01137695/registered